DE60334378D1 - Zusammensetzung zur kontrollierten wirkstoffabgabe - Google Patents

Zusammensetzung zur kontrollierten wirkstoffabgabe

Info

Publication number
DE60334378D1
DE60334378D1 DE60334378T DE60334378T DE60334378D1 DE 60334378 D1 DE60334378 D1 DE 60334378D1 DE 60334378 T DE60334378 T DE 60334378T DE 60334378 T DE60334378 T DE 60334378T DE 60334378 D1 DE60334378 D1 DE 60334378D1
Authority
DE
Germany
Prior art keywords
active compound
particles
coated
composition
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334378T
Other languages
English (en)
Inventor
Christopher J Speirs
Peter Moir
Richard Williams
Michael Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temrel Ltd Virgin Islands
Original Assignee
Temrel Ltd Virgin Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30117101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60334378(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0215656A external-priority patent/GB0215656D0/en
Priority claimed from GB0215657A external-priority patent/GB0215657D0/en
Application filed by Temrel Ltd Virgin Islands filed Critical Temrel Ltd Virgin Islands
Application granted granted Critical
Publication of DE60334378D1 publication Critical patent/DE60334378D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE60334378T 2002-07-05 2003-07-04 Zusammensetzung zur kontrollierten wirkstoffabgabe Expired - Lifetime DE60334378D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0215656A GB0215656D0 (en) 2002-07-05 2002-07-05 Controlled release composition
GB0215657A GB0215657D0 (en) 2002-07-05 2002-07-05 Controlled release composition for the treatment of inflammatory bowel disease
PCT/GB2003/002911 WO2004004696A1 (en) 2002-07-05 2003-07-04 Controlled release composition

Publications (1)

Publication Number Publication Date
DE60334378D1 true DE60334378D1 (de) 2010-11-11

Family

ID=30117101

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334378T Expired - Lifetime DE60334378D1 (de) 2002-07-05 2003-07-04 Zusammensetzung zur kontrollierten wirkstoffabgabe

Country Status (15)

Country Link
US (4) US20060127484A1 (de)
EP (1) EP1519717B1 (de)
JP (1) JP2005532387A (de)
CN (1) CN1665490A (de)
AT (1) ATE482694T1 (de)
AU (1) AU2003244840C1 (de)
BR (1) BR0312347A (de)
CA (1) CA2491355A1 (de)
DE (1) DE60334378D1 (de)
DK (1) DK1519717T3 (de)
MX (1) MXPA05000128A (de)
NZ (1) NZ537632A (de)
PL (1) PL374922A1 (de)
RU (1) RU2336865C2 (de)
WO (1) WO2004004696A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
BRPI0417985A (pt) 2003-12-23 2007-04-17 Temrel Ltd uso de água para controlar o tamanho de partìculas, e, processo para a produção de partìculas para uso em uma composição farmacêutica
US9875508B1 (en) 2004-11-19 2018-01-23 Allstate Insurance Company Systems and methods for customizing insurance
US10282785B1 (en) 2004-11-19 2019-05-07 Allstate Insurance Company Delivery of customized insurance products and services
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
AU2007215304B2 (en) * 2006-02-09 2012-06-14 Alba Therapeutics Corporation Formulations for a tight junction effector
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
ES2497494T3 (es) 2006-06-21 2014-09-23 Opko Renal, Llc Método de tratamiento y prevención del hiperparatiroidismo secundario
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
US8465768B2 (en) * 2008-11-07 2013-06-18 Samyang Biopharmaceuticals Corporation Pharmaceutical compositions for release control of methylphenidate
US20100143437A1 (en) * 2008-12-09 2010-06-10 Morris Edward J Implantable analgesic
EP2298321A1 (de) * 2009-08-26 2011-03-23 Nordic Pharma Neuartige pharmazeutische Zusammensetzungen zur Behandlung von IBD
CN105394354A (zh) * 2010-01-15 2016-03-16 凯敏工业公司 受保护的α-淀粉酶
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR101423237B1 (ko) * 2010-05-04 2014-07-30 주식회사 삼양바이오팜 탐스로신 또는 이의 약학적으로 허용 가능한 염을 포함하는 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CN103648486A (zh) * 2011-05-06 2014-03-19 葛兰素史密斯克莱有限责任公司 缓释对乙酰氨基酚制剂
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EP2753310B1 (de) * 2011-09-07 2021-03-24 Roland Saur-Brosch Formulierung zur kontrollierten freisetzung eines oder mehreren stoffe im verdauungstrakt eines säugetiers
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
GB201210184D0 (en) * 2012-06-11 2012-07-25 Univ Leuven Kath Formulations of metronidazole for the treatment of pouchitis
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3193925A2 (de) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunktive therapie mit 25-hydroxyvitamin d
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
IL290855B1 (en) 2016-03-28 2024-02-01 Eirgen Pharma Ltd Treatment methods using vitamin D
AU2017356350B2 (en) * 2016-11-09 2024-02-29 Engene, Inc. Intestinal expression of programmed death ligand 1
EP4233902A3 (de) * 2016-12-14 2024-02-28 Biora Therapeutics, Inc. Behandlung einer krankheit des gastrointestinalen traktus mit einem integrin-hemmer
US11033490B2 (en) 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
BR112019011689A2 (pt) * 2016-12-14 2019-10-22 Progenity Inc tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
CN108822816A (zh) * 2018-06-25 2018-11-16 中国石油集团渤海钻探工程有限公司 一种疏松砂岩用可酸溶凝胶堵漏剂及其制备方法
CN113929807B (zh) * 2021-06-25 2022-09-27 贵州省欣紫鸿药用辅料有限公司 一种烯烃酸树脂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa
DE19724696A1 (de) * 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
EP1064938A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Dosierungsformen zur kontrollierte Wirkstoffabgabe mit mindenstens ein pulsierendem Zeitverlauf
US8728445B2 (en) * 2001-05-01 2014-05-20 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences Hydrogel Compositions

Also Published As

Publication number Publication date
DK1519717T3 (da) 2011-01-10
JP2005532387A (ja) 2005-10-27
EP1519717A1 (de) 2005-04-06
BR0312347A (pt) 2005-04-12
CA2491355A1 (en) 2004-01-15
US20130230588A1 (en) 2013-09-05
CN1665490A (zh) 2005-09-07
RU2005102838A (ru) 2005-08-10
EP1519717B1 (de) 2010-09-29
MXPA05000128A (es) 2005-09-30
RU2336865C2 (ru) 2008-10-27
US20060127484A1 (en) 2006-06-15
US20140322317A1 (en) 2014-10-30
US20110182986A1 (en) 2011-07-28
NZ537632A (en) 2006-06-30
PL374922A1 (en) 2005-11-14
WO2004004696A1 (en) 2004-01-15
ATE482694T1 (de) 2010-10-15
AU2003244840B2 (en) 2009-09-10
AU2003244840A1 (en) 2004-01-23
AU2003244840C1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
DE60334378D1 (de) Zusammensetzung zur kontrollierten wirkstoffabgabe
MX9701465A (es) Formulacion de acetaminofeno, de liberacion sostenida.
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
WO2008132710A3 (en) Pharmaceutical nimodipine compositions
MY148805A (en) Controlled release preparation
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
MX2009013497A (es) Metodo para mejorar el crecimiento de una planta.
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
EA200500909A1 (ru) Модифицированное высвобождение фармацевтической композиции
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
HUP0203813A3 (en) Aminobenzophenones as inhibitors of il-1betha and tnf-alpha, pharmaceutical compositions containing them and their use
TW200727925A (en) Air treatment compositions and devices therefor
HRP20060136A2 (en) Pellets containing venflaxine hydrochloride
IL164221A0 (en) Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
WO2006049564A8 (en) New modified release pellet formulations for proton pump inhibitors
WO2005123045A3 (en) Controlled release matrix pharmaceutical dosage formulation
EA200300110A1 (ru) Композиция элетриптана в виде частиц
NO20075715L (no) Depotsammensetning omfattende cefalosporin for behandling av en bakterieinfeksjon